Discontinuing drug treatments
BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g7013 (Published 21 November 2014) Cite this as: BMJ 2014;349:g7013- Danijela Gnjidic, lecturer and NHMRC early career fellow12,
- David G Le Couteur, professor of geriatric medicine23,
- Sarah N Hilmer, head of department of clinical pharmacology24
- 1Faculty of Pharmacy, University of Sydney, Sydney, NSW, Australia
- 2Sydney Medical School, University of Sydney, Sydney, NSW, Australia
- 3Ageing and Alzheimers Institute and Concord Hospital, Sydney, NSW, Australia
- 4Royal North Shore Hospital and Kolling Institute of Medical Research, Sydney, NSW, Australia
- danijela.gnjidic{at}sydney.edu.au
Deprescribing is the process of withdrawing drugs in an attempt to improve patient outcomes. Emerging evidence from studies of patients with multimorbidity and older people, who are a large and growing proportion of the population, shows that deprescribing may be linked to improvements in survival and quality of life.1 2 While it is sometimes asserted that patients are unwilling to have their drugs withdrawn, in a recent survey over 90% of patients reported that they would be willing to stop taking one or more of their medicines.3 Deprescribing should be considered during every regular review of a patient.
The principles of prescribing and deprescribing are highly comparable,4 although with obvious differences. Prescribing new drugs involves diagnosing a problem and establishing an indication; deprescribing involves establishing which drug may be causing a problem (an adverse drug event) or which drug does not have a current indication. Prescribing involves applying specific disease based guidelines to a patient; deprescribing involves optimising all treatments to achieve individual care goals. While prescribing for people with multimorbidity is commonly driven by guidelines that are based on single diseases, the …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.